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Abstract
Background: Ventricular fibrillation is routinely induced during implantable cardioverter-
-defibrillator insertion to assess defibrillator performance, but this strategy is experiencing  
a progressive decline. We aimed to assess the efficacy of defibrillator therapies and long-term 
outcome in a cohort of patients that underwent defibrillator implantation with and without 
defibrillation testing.
Methods: Retrospective observational series of consecutive patients undergoing initial defi-
brillator insertion or generator replacement. We registered spontaneous ventricular arrhyth-
mias incidence and therapy efficacy, and mortality.
Results: A total of 545 patients underwent defibrillator implantation (111 with and 434 
without defibrillation testing). After 19 (range 9–31) months of follow-up, the death rate per 
observation year (4% vs. 4%; p = 0.91) and the rate of patients with defibrillator-treated ven-
tricular arrhythmic events per observation year (with test: 10% vs. without test: 12%; p = 0.46) 
were similar. The generalized estimating equations-adjusted first shock probability of success 
in patients with test (95%; CI 88–100%) vs. without test (98%; CI 96–100%; p = 0.42) and 
the proportion of successful antitachycardia therapies (with test: 87% vs. without test: 80%;  
p = 0.35) were similar between groups. There was no difference in the annualized rate of failed 
first shock per patient and per shocked patient between groups (5% vs. 4%; p = 0.94).
Conclusions: In this observational study, that included an unselected population of patients 
with a defibrillator, no difference was found in overall mortality, first shock efficacy and rate of 
failed shocks regardless of whether defibrillation testing was performed or not. (Cardiol J 2015; 
22, 3: 253–259)
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Introduction
The assessment of defibrillation efficacy has 
long been the standard of care during implantable 
cardioverter-defibrillator (ICD) insertion, and is 
recommended by ICDs manufacturers and scien-
tific guidelines [1, 2]. However, this strategy is 
currently being questioned due to the high prob-
ability of current devices to successfully defibril-
late ventricular arrhythmias, the low incidence of 
spontaneous ventricular fibrillation (VF) (~10%) 
and the high efficacy of dedicated antitachycardia 
pacing (ATP) strategies [2–8]. Moreover, defibrilla-
tion testing (DT) is not without a risk, and compli-
cations associated to VF induction, shock delivery 
and anesthesia may occur [2, 3, 9–12]. For all these 
reasons, the proportion of patients undergoing any 
type of DT, especially among primary prevention 
ICD implantation, is experiencing a progressive 
decline in routine clinical practice [12–15]. The 
prospective, non-randomized SAFE-ICD study se-
lected centers according to their common practice 
of performing or not performing DT at implantation 
and found no different outcome between groups [8]. 
However, that study only included de-novo implants 
and did not report data on ATP therapy.
The purpose of the present study was to as-
sess the efficacy of ICD therapies (both shocks and 
ATP) and long-term clinical outcome in a cohort 
of consecutive patients, including de-novo implants 
and generator replacements, that underwent ICD 
implantation with (+) and without (–) DT at the 
time of ICD insertion.
Methods
We retrospectively reviewed the records 
of a series of consecutive patients > 18 years 
old, in whom an ICD had been implanted in two 
tertiary-care teaching hospitals (Hospital General 
Universitario Gregorio Marañón and Rabin Medical 
Center) during a period of 3 years, following the 
implementation of a non-DT policy at our institu-
tions. DT was recommended in right pectoral ICD 
implantation, R wave signal < 5 mV or not able 
to be measured due to pacing, abandoned leads, 
implanted electronic devices, chronic treatment 
with amiodarone and patients with hypertrophic 
cardiomyopathy or channelopathies. However, the 
final decision to test was left at the discretion of the 
operator. In case any type of DT was considered 
necessary defibrillation safety margin estimation 
was routinely performed [16]. In the DT+ group, 
VF was induced by standard T-wave shock or 
a 50-Hz burst. A protocol of 2 defibrillations at 10 J 
below the maximum output of the device was 
applied with a 5-min rest period between VF in-
ductions. If the first shock failed, but the second 
was successful, the patient was also considered to 
have adequate DT. If the defibrillation attempt was 
unsuccessful certain strategies were adopted to 
overcome this situation (i.e. right ventricular [RV] 
lead repositioning) and the protocol was repeated. 
All patients signed written informed consent. All 
spontaneous tachyarrhythmic episodes with ICD 
stored electrograms that resulted in ventricular 
therapies were reviewed by two independent ob-
servers (C.H. and P.C.), to assess efficacy of the 
delivered therapy. Disagreements were resolved 
by consensus with a third observer.
All ICD implantations were performed at the 
electrophysiology laboratory under local anesthesia 
and conscious sedation. Only pectoral implanta-
tions with dual-coil shocking leads placed in the 
RV apex were included in the study. Patients re-
ceived high-output (≥ 35 J) or standard active can 
devices manufactured by Medtronic (Minneapolis, 
MN, USA), Boston Scientific (St. Paul, MN, USA) 
or Biotronik (Berlin, Germany). Device program-
ming was performed according to patient clinical 
status and left at the discretion of the responsible 
physician, but all shocks were programmed at the 
highest available output of the device. However, 
a standardized ATP programming in the fast ven-
tricular tachycardia (VT) zone was recommended 
in all patients [17]. Patients were first followed 
3 months after device implantation and every 
6 months thereafter.
Statistical analysis
We used an approximate normal test for the 
equality of rates for sample size estimation, where 
a total of 111 patients in the DT+ group and 434 in 
the DT– group would be able to detect an absolute 
error in mortality rates of 0.06, with 80% statistical 
power and a significance level of 5%. Continuous 
variables were assessed for normality using the 
Wilk-Shapiro test. Normally distributed variables 
are expressed as mean ± standard deviation, 
whereas those with nonparametric distribution are 
presented as median and interquartile range (IQR). 
Categorical variables are reported as number and 
percentage. Comparisons of normal continuous 
baseline characteristics were made using Student’s 
t-test. In case of non-normally distributed con-
tinuous variables, nonparametric tests were used. 
Comparisons of categorical varia bles were done us-
ing the Fisher’s exact test or c2 test, as appropriate. 
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Incidence rates of death and arrhythmic events 
between the cohorts of DT+ and DT– patients 
were compared using an approximate normal test 
for the equality of rates. The annualized rate for 
each arrhythmic episode type per patient month 
was calculated by dividing the total number of 
episodes by type by months of follow-up for each 
patient group (DT+ vs. DT–), where the weight 
assigned to each patient is the proportion of overall 
follow-up that the patient contributed to the aggre-
gate follow-up [7]. Annualized rates of events per 
patient in both cohorts were compared using the 
Generalized Linear Model (GLZM) and the Wald 
c2 test. Generalized estimating equations (GEE) 
method was used to compare the efficacy of ICD 
therapies in the two cohorts, adjusting for multiple 
episodes per patient [18]. Kaplan-Meier survival 
curves and log-rank test were used to compare sur-
vival between both groups. For statistical analysis 
we used SPSS version 19.0 (SPSS Inc.; Chicago, 
IL). All probability (p) values were 2-sided and 
statistical significance was established at p < 0.05.
Results
We included 548 consecutive patients that 
represent the total number of ICD implants per-
formed at the participating centers during the 
inclusion period at each site, including generator 
replacements. Patients were followed for a median 
of 19 months (IQR 9–31). Three (0.68%) patients 
could not be contacted and were considered lost 
to follow-up and excluded from analysis. Table 1 
shows the clinical characteristics of patients in-
cluded in the study. In 111 (20%) patients, DT 
was performed at the time of ICD implantation. 
DT+ patients were slightly younger, less likely to 
receive a cardiac resynchronization therapy with 
defibrillation capabilities (CRT-ICD) and more 
likely to be treated with antiarrhythmic drugs and 
to receive a dual-chamber device. Other baseline 
clinical characteristics were comparable between 
groups.
Patients’ clinical outcomes
Patients in the DT+ group were followed for 
a longer period than DT– patients (32 [18–45] vs. 
15 [9–26] months; p < 0.001). After adjusting the 
event rate by the follow-up duration, there was no 
significant difference in the death rate per observa-
tion year (DT+: 0.04 vs. DT–: 0.04; p = 0.91) nor 
in the rate of patients with ventricular arrhythmic 
events per observation year (DT+: 0.10 vs. DT–: 
0.12; p = 0.46) (Table 2). Similarly, there was no 
difference in the rate of patients with VF per ob-
servation year and only a trend towards a slightly 
higher rate of patients with VT per observation 
year in the DT– group.
Table 1. Patients’ baseline characteristics.
Variable DT+ (n = 111) DT– (n = 434) P
Age [years] 67 (54–74) 68 (59–76) 0.03*
Male 95 (86%) 360 (83%) 0.52**
Heart disease etiology:
Ischemic 80 (72%) 279 (64%) 0.12**
Dilated cardiomyopathy 12 (11%) 77 (18%) 0.08**
Channelopathies 5 (4.5%) 10 (2.3%) 0.20**
Hypertrophic cardiomyopathy 6 (5.4%) 22 (5%) 0.88**
Other 8 (7%) 46 (10%) 0.28**
Ejection fraction £ 0.35 69/111 (62%) 300/413 (73%) 0.16**
Indication secondary prevention 69 (62%) 227 (52%) 0.08**
De novo ICD implantation 95 (86%) 349 (80%) 0.22**
Type of ICD: < 0.01**
Single chamber 72 (65%) 270 (62%) NS***
Dual chamber 21 (19%) 44 (10%) 0.01***
CRT-ICD 18 (16%) 120 (28%) 0.01***
Antiarrhythmic drug therapy (amiodarone) 38 (34%) 95 (22%) 0.01**
Continuous variables are expressed as median and interquartile range; *Mann-Whitney U test. Sig 2-sided; **Pearson’s c2 test. Sig 2-sided; 
***Approximate normal test for adjusted residuals. Sig. 2-sided; CRT-ICD — cardiac resynchronization therapy with defibrillation capabilities; 
DT — defibrillation testing; ICD — implantable cardioverter-defibrillator; NS — not significant
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ICD therapy frequency and efficacy  
by DT group at implant
During the follow-up period, 109 (20%) pa-
tients experienced 449 ventricular arrhythmic 
episodes that required ICD therapy. The absolute 
proportion of shocked patients was higher in the 
DT+ group (22% vs. 11%; p < 0.01). However, 
after adjusting for the follow-up duration, there 
was no difference in the annualized rate of patients 
receiving shocks or ATP therapies, between DT+ 
vs. DT– groups (Table 2).
As shown in Table 3, there was no difference in 
the GEE-adjusted first shock probability of success 
in patients with DT+ (95%; CI 88–100%) vs. DT– 
(98%; CI 96–100%; p = 0.42). The proportion of 
successful ATP therapies was greater in the DT+ 
group, but the difference was not significant (DT+: 
87% vs. DT–: 73%; p = NS).
Five patients had a failed appropriate first shock: 
2 patients in the DT+ group and 3 in the DT– group 
(Table 4). This accounts for 2.8% (5/179) of total 
appropriate ICD shocks delivered in the study and 
0.9% (5/545) of patients followed in the study. After 
adjusting for the differences in follow-up duration, 
there was no difference between groups in the an-
nualized rate of failed first shock per patient (DT+: 
0.01 vs. DT–: < 0.01; p = 0.71) and per shocked 
patient (DT+: 0.05 vs. DT–: 0.04; p = 0.94). Table 4 
shows the clinical characteristics of patients with 
a failed first shock. In all cases, the second shock 
successfully terminated the ventricular arrhythmia.
Mortality
Forty (7.3%) patients died during the follow- 
-up: 13 in the DT+ group (6 non-sudden cardiac 
Table 2. Patients’ clinical outcomes during follow-up.
Incidence rate (patient-year observation) DT+ (n = 11) DT– (n = 434) P
Death 0.04 0.04 0.91
Patients with ventricular arrhythmic events: 0.10 0.12 0.46
Patients with ventricular fibrillation 0.08 0.05 0.16
Patients with ventricular tachycardia 0.05 0.09 0.07
Patients with therapies: 0.10 0.12 0.46
Shock 0.08 0.07 0.69
Antitachycardia pacing 0.05 0.07 0.16
Approximate normal test for equality of rates. Sig. 2-sided; DT — defibrillation testing







Successful shocks 38 136




Successful ATP 79 196
Failed ATP 46 133
Successful ATP/ATP ± 87% 80% 0.35
± Generalized estimating equations adjustment to account for mul-
tiple episodes; ATP — antitachycardia pacing; DT — defibrillation 
testing
Table 4. Clinical characteristics of patients with a failed first ICD shock.
Case Gender Age Etiology EF Device Indication: 
Prevention
DT Event Zone AAD 2nd ICD 
shock
1 Male 70 Non-ischemic 0.15 CRT-ICD Primary – M-VT VF Yes Successful
2 Male 61 Ischemic 0.30 SC-ICD Secondary – M-VT VF No Successful
3 Male 60 Non-ischemic 0.20 SC-ICD Secondary – P-VT VF No Successful
4 Male 59 Ischemic 0.30 DC-ICD Secondary + VF VF Yes Successful
5 Male 65 Ischemic 0.25 SC-ICD Secondary + VF VF Yes Successful
ICD — implantable cardioverter-defibrillator; EF — ejection fraction; Zone — ICD detection zone; AAD — antiarrhythmic drug therapy;  
SC-ICD — single-chamber ICD; DC-ICD — dual-chamber ICD; M-VT — monomorphic ventricular tachycardia; P-VT — polymorphic ventricular 
tachycardia; VF — ventricular fibrillation
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deaths; 4 non-cardiac deaths; 2 sudden deaths; 
1 unknown cause) and 27 in the DT– group 
(11 non-sudden cardiac death; 11 non-cardiac death; 
2 electrical storm; 3 unknown causes). Patients 
dying due to electrical storm were admitted to 
the hospital with incessant ventricular arrhythmia 
that was treated with multiple appropriate ICD dis-
charges that terminated the episodes with the first 
shock in all instances, while the ICD was working 
properly. One sudden death in the DT+ group oc-
curred in 1 patient with hypertrophic cardiomyo-
pathy. Unknown deaths were non-sudden and no 
shock delivery occurred. There were no deaths 
related to device failure or malfunction.
Unadjusted mortality rates were higher in 
patients with (12%) vs. without DT (6.2%; p = 
= 0.048). However, after adjusting for the differ-
ences in follow-up duration, there was no difference 
in the annualized rate of death in DT+ vs. DT– pa-
tients (Table 2). As shown in Figure 1, there were 
no significant differences in the observed survival 
rates between DT+ vs. DT– patients (p = 0.9).
Discussion
This observational study in an unselected 
population of consecutive patients undergoing 
ICD implantation found similar shock efficacy and 
long-term clinical outcome regardless of whether 
DT was performed or not. Therefore, in our study, 
performing DT did not predict ICD performance 
and had no clinical impact during the follow-up. 
These results are representative of the overall 
population of patients currently undergoing all 
types of ICD implants at two tertiary referral 
centers, for all kinds of ICD indications, including 
ICD with CRT capabilities and generator replace-
ments. Finally, these results are representative 
of the clinical outcomes of the transition from the 
traditional DT strategy to the non-DT strategy for 
most of the patients.
Clinical impact of DT
ICD implantation is indicated to reduce all-
cause mortality in patients at risk. In the present 
study, we observed no differences in the overall 
mortality rates irrespective of whether DT was 
performed or not. All-cause mortality rates were 
similar in the RAFT pilot trial [19], but lower than 
lower in others observational or retrospective 
studies [8, 20, 21]. Differences in patient charac-
teristics and follow-up duration might account for 
these apparent discrepancies. Nevertheless, none 
of these studies were powered to detected differ-
ences in all-cause mortality and sudden cardiac 
death. On the other hand, in agreement with prior 
studies, there was no difference between groups 
in the annualized rate of patients with ventricular 
arrhythmic episodes and the annualized rate of 
patients receiving appropriate shocks (8% vs. 9%) 
[19–21].
ICD therapy efficacy in DT+ vs. DT–  
patients
The efficacy of ICD to successfully defibrillate 
induced VF at implant is considered an adequate 
surrogate of ICD efficacy during follow-up [22]. In 
the present study, first shock efficacy was 97% and 
Figure 1. Kaplan-Meier estimates of survival in patients with (DT+) and without (DT–) defibrillation testing.
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only 5 episodes required a second shock to suc-
cessfully terminate the arrhythmia, with no differ-
ences between DT+ (95%) vs. DT– (98%) groups. 
This comparison cannot be assessed statistically 
due to the small number of unsuccessful shocks. 
This rate of first shock failure is in agreement to 
that reported for spontaneous VF in patients with 
DT (80–91%) or safety margin testing (91%) at 
ICD implantation [2, 4, 5]. Similarly, a significant 
proportion (80–87%) of VT/fast VT episodes were 
successfully ATP-terminated without shock deliv-
ery, regardless of whether DT was performed. This 
is consistent with previous studies showing that 
dedicated ATP programming reduce the need for 
shocks to terminate VT/VF in a substantial number 
of patients [7, 17, 23]. In addition, newer devices 
are able to deliver ATP during energy charge when 
treating a VF episode, in an attempt to terminate 
a fast VT detected in the VF zone [24, 25]. Interest-
ingly, we observed no first shock failures following 
ineffective ATP therapies, both in DT+ and DT– 
patients, since all first shocks were programmed 
at maximum energy [23].
Prior studies
Prior retrospective [5, 20, 21], prospective 
observational [8] and small randomized [19] studies 
have reported on the long-term clinical outcome of 
non-tested vs. patients undergoing DT, mostly in 
mixed population of primary prevention and CRT-D 
patients. Despite differences in design, patients’ 
characteristics and follow-up duration, our results 
are in agreement with most of these studies. Pires 
and Johnson [5] reported a retrospective analysis of 
ICD patients assigned to intraoperative DT, limited 
defibrillation safety margin testing or no DT in 
a non-randomized fashion, and found no difference 
in shocks efficacy and sudden death rate, but 
a higher overall mortality in the non-tested group. 
Bianchi et al. [21] retrospectively compared the 
clinical outcome of ICD recipients for primary 
prevention from centers that routinely performed 
DT to that of patients in whom no DT was per-
formed, and found no difference in total mortality, 
cardiovascular mortality or sudden death rates 
between those groups. Similarly, no differences 
in survival free of heart transplantation or shock 
efficacy were found in a retrospective study of 
CRT-D patients [20]. A small pilot sub-study of the 
RAFT trial, compared patients with and without 
DT in a randomized fashion and showed similar 
ICD therapy efficacy but a non-significant 2-fold 
increased all-cause mortality in patients undergo-
ing DT [19]. In the largest study reported to date, 
the SAFE-ICD study prospectively followed 2,120 
patients from centers selected according to their 
standard implantation practice and found a similar 
long-term outcome in patients with DT vs. without 
DT during de novo implants, in terms perioperative 
complications, ICD therapy efficacy and mortality 
[8]. Despite the smaller sample size, our study 
agrees with the SAFE-ICD in their prospective, 
non-randomized nature, and the lack of outcome 
differences between groups. However, in our study, 
no patients were excluded during the recruitment 
period and all types of ICD implants were consid-
ered, including generator replacements. Thus, our 
study confirms and further expands the SAFE-ICD 
study results in patients that most likely represent 
an unselected population currently undergoing ICD 
implantation with regards to age, gender, indica-
tion and device type [14, 16]. Moreover, this is 
the first study to provide detailed analyses of the 
outcome of ICD therapies, both ATP and shocks, 
showing a similar first shock efficacy in patients 
following failed ATP therapy in patients with and 
without DT at implant. Since ATP therapy failure 
delays time to shock and prolongs VF duration, 
a lower shock efficacy could have been expected in 
this context [23, 26]. It is reassuring to note that 
in our study, all VT/VF episodes following failed 
ATP were successfully converted when first shock 
was programmed at maximum energy, regardless 
DT was performed or not.
Limitations of the study
Our study has several potential limitations. 
This is a non-randomized retrospective study with 
different follow-up times between groups that were 
adjusted by calculating annualized event rates. Se-
lection bias towards including patients with lower 
DT thresholds in the non-tested group cannot be 
excluded. Non-tested patients had lower ejection 
fraction and this difference may explain the higher 
rate of CRT implantation in this group. Second, as 
only dual-coil ICD leads were implanted, our find-
ings should not be extrapolated to patients with 
single-coil leads. Third, ICD programming was not 
guided by the result of DT in the tested group and 
first shocks were set at maximum energy in both 
groups. The remaining ICD parameters settings 
were left at the physicians’ discretion and were not 
available for analyses. Nevertheless, the recom-
mended ATP programming strategy was able to 
successfully terminate a high proportion of treated 
episodes in previous studies [7, 17, 26]. Finally, 
3 patients died for unknown causes, but witnesses’ re- 
ports reasonably excluded a sudden cause of death.
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Conclusions
In this observational study, that included an 
unselected population of consecutive patients 
undergoing ICD implantation, performing DT at 
the time of ICD insertion was not associated with 
improved survival, higher first shock efficacy 
probability or lower rate of failed ICD shocks as 
compared to the strategy of withholding DT. Until 
the results of randomized clinical trials become 
available [22], the present study questions the need 
for systematically performing DT in the majority 
of patients undergoing ICD implantation.
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